Andris Skride

Medicine & Life Sciences

1. Venous Thromboembolism 100%
2. Pulmonary Hypertension 97%
3. Registries 89%
4. Pulmonary Embolism 84%
5. Pulmonary Arterial Hypertension 62%
6. Anticoagulants 42%
7. 3-(2,2,2-trimethylhydrazine)propionate 40%
8. Mortality 25%
9. Familial Primary Pulmonary Hypertension 24%
10. Hemorrhage 23%
11. Lung 21%
12. Vitamin K 20%
13. Dabigatran 20%
14. Therapeutics 20%
15. Endarterectomy 19%
16. Latvia 18%
17. Energy Metabolism 16%
18. Monocrotaline 15%
19. Venous Thrombosis 15%
20. Atrial Fibrillation 15%
21. Exercise 14%
22. Thrombosis 14%
23. Recurrence 14%
24. Theoretical Models 14%
25. Hemodynamics 14%
26. University Hospitals 12%
27. Heart Diseases 12%
28. Upper Extremity Deep Vein Thrombosis 12%
29. Stroke 11%
30. Vena Cava Filters 11%
31. fibrin fragment D 11%
32. Left Ventricular Dysfunction 11%
33. Survival 10%
34. Hereditary Hemorrhagic Telangiectasia 10%
35. Dasatinib 10%
36. Balloon Angioplasty 10%
37. Vascular Resistance 10%
38. Splenectomy 10%
39. Neoplasms 10%
40. Myeloproliferative Disorders 9%
41. Blood Pressure 9%
42. Coronavirus 9%
43. Antiphospholipid Syndrome 9%
44. Idiopathic Thrombocytopenic Purpura 9%
45. Natural History 9%
46. Cardiac Catheterization 8%
47. Hypothermia 7%
48. Self Efficacy 7%
49. Heart Ventricles 7%
50. Ventricular Pressure 7%